Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1–3 newly diagnosed brain metastases

Journal of Neuro-Oncology

Volumn 124, Issue 3, 2015, Pages 485-491

  Ahluwalia, Manmeet S ^a,b,e   Chao, Samuel T ^a,b,e   Parsons, Michael W ^a   Suh, John H ^a,b,e   Wang, Ding ^c   Mikkelsen, Tom ^c   Brewer, Cathy J ^a,b,e   Smolenski, Kathy N ^a,b,e   Schilero, Cathy ^a,b,e   Rump, Matthew ^a,b   Elson, Paul ^a,b   Angelov, Lilyana ^a,e   Barnett, Gene H ^a,e   Vogelbaum, Michael A ^a,e   Weil, Robert J ^d   Peereboom, David M ^a,b,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Brain metastases; Neuropsychological testing; Phase 2; Secondary prevention; Stereotactic radiosurgery; Sunitinib

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; COGNITION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMOLYSIS; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MELANOMA; MIDDLE AGED; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NEUROPSYCHOLOGICAL TEST; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RASH; STEREOTACTIC RADIOSURGERY; STOMATITIS; TREATMENT DURATION; UTERINE CERVIX CANCER; UTERUS CARCINOMA; VERY ELDERLY; ADVERSE EFFECTS; BRAIN NEOPLASMS; CLINICAL TRIAL; COGNITION DISORDERS; MULTIMODALITY CANCER THERAPY; PROCEDURES; RADIATION RESPONSE; RADIOSURGERY; SALVAGE THERAPY; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COGNITION DISORDERS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INDOLES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROPSYCHOLOGICAL TESTS; PYRROLES; RADIOSURGERY; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84942500983     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1862-6     Document Type: Article

References (22)

1. Kaal EC, Niel CG, Vecht CJ (2005) Therapeutic management of brain metastasis. Lancet Neurol 4:289–298
2. Delattre JY, Krol G, Thaler HT, Posner JB (1988) Distribution of brain metastases. Arch Neurol 45:741–744
3. Sundstrom JT, Minn H, Lertola KK, Nordman E (1998) Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 30:296–299
4. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751
5. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1–9
6. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500
7. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672
8. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489
9. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491
10. Aoyama H, Tago M, Shirato H, for the Japanese Radiation Oncology Study Group 99–1 (JROSG 99–1) Investigators (2015) Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 1:E1–E8
11. O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605
12. Kim LS, Huang S, Lu W, Lev DC, Price JE (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21:107–118
13. Roodink I, van der Laak J, Kusters B, Wesseling P, Verrijp K, de Waal R, Leenders W (2006) Development of the tumor vascular bed in response to hypoxia-induced VEGF-A differs from that in tumors with constitutive VEGF-A expression. Int J Cancer 119:2054–2062
14. Benedict R, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test: Revised—Normative data and analysis of inter-form and test-retest reliablity. Clin Neuropsychol 12:43–55
15. Benton A, Hamsher K, Sivan A (1983) Multilingual Aphasia examination. AJA Associates, Iowa City
16. Lezak MD (2004) Neuropsychological assessment, 4th edn. Oxford University Press, Oxford
17. Jacobson NS, Truax P (1991) Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59:12–19
18. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165
19. Frytak S, Shaw JN, O’Neill BP, Lee RE, Eagan RT, Shaw EG, Richardson RL, Coles DT, Jett JR (1989) Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 12:27–33
20. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski MK, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G, Suh JH, Mehta MP (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85:1312–1318
21. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B (2010) Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 21:1027–1031
22. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117:4958–4965